Mirapex ER (pramipexole) Extended-release Tablets
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) –
January 2016
ADVERSE REACTIONS
Postmarketing Experience
…skin reactions (including erythema, rash, pruritus,...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts
More News: Drugs & Pharmacology | Skin